Can steroids boost lung blood flow in COPD? small trial investigates

NCT ID NCT05607719

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding inhaled corticosteroids to standard COPD treatment improves blood vessel function in the lungs. Thirty adults with COPD, aged 40-80, will take either Bevespi or Bretzri for four weeks. Researchers will measure how well lung blood vessels widen after inhaling albuterol, a common rescue inhaler.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
inhaled corticosteroids (Bevespi and Bretzri)
What this could lead to
If successful, this could show that adding inhaled corticosteroids to standard COPD therapy improves blood vessel function in the lungs, potentially leading to better disease management.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to all COPD patients. The study focuses on a short-term measure of blood vessel function, not long-term outcomes like quality of life or survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.